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Introduction
Arsenic (As), and specifically its inorganic 
forms (iAs) [arsenite (iAsIII) and arsenate 
(iAsV)], are naturally occurring drinking-water 
contaminants. Epidemiologic evidence (James 
et al. 2013; Kuo et al. 2013; Maull et al. 2012; 
Pan et al. 2013; Wang et al. 2014), including a 
prospective study (Kim et al. 2013), has linked 
chronic iAs exposure with the risk of diabetes 
mellitus. Several mechanisms by which iAs 
exposure can disrupt glucose homeostasis 
have been proposed (Maull et al. 2012). 
Trivalent iAsIII and the trivalent methylated 
arsenicals that are produced in the course of 
iAs metabolism—methylarsonite (MAsIII) 
and dimethyl arsinite (DMAsIII)—play key 
roles in these mechanisms (Douillet et al. 
2013; Fu et al. 2010; Paul et al. 2007, 2008). 
However, assessing the association between 
these arsenicals and risk of diabetes in popula-
tion studies has been a major challenge. This 
is because iAsIII—and particularly MAsIII 
and DMAsIII—are unstable in human urine, 
which has been traditionally used in assessing 
iAs exposure and metabolism (Del Razo et al. 
2011; Gong et al. 2001). An additional chal-
lenge is associated with quantification of iAs 
metabolites in urine, specifically with using 
urinary creatinine as a factor to adjust for 
variation in urine dilution. Urinary creatinine 
concentration is influenced by various factors, 
including age, sex, health status, ethnicity, 
body mass index (BMI), fat-free mass, and 
time of collection (Barr et al. 2005; Boeniger 
et al. 1993; Mahalingaiah et al. 2008). In 
addition, adjusting for creatinine may be 
 inappropriate for individuals with compro-
mised renal function, including people with 
diabetes (Jerums et al. 2010). More impor-
tantly, iAs exposure may lead to an increased 
excretion of creatinine (Nermell et al. 2008). 
Thus, the analysis of iAs metabolites in 
body fluids other than urine, such as in cells 
or tissues, may provide a better measure of 
iAs exposure.
We have previously demonstrated the 
feasibility of As analysis in human cells, 
including exfoliated urothelial cells (EUC). 
In 2008, we used hydride generation (HG)–
cryotrapping (CT)–atomic absorption spec-
trometry (AAS) to measure concentrations 
of total iAs (iAsIII + V), MAs (MAsIII + V), and 
DMAs (DMAsIII + V) in EUC isolated from 
the urine of residents of the Zimapan region 
in Mexico (Hernández-Zavala et al. 2008b). 
Because of small sample sizes, we could not 
perform the oxidation state-specific analysis 
to distinguish between AsIII and AsV species. 
However, we were able to detect and quantify 
both AsIII and AsV species in cultured human 
urothelial cells treated in vitro with iAs. We 
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Background: A growing number of studies link chronic exposure to inorganic arsenic (iAs) with 
the risk of diabetes. Many of these studies assessed iAs exposure by measuring arsenic (As) species 
in urine. However, this approach has been criticized because of uncertainties associated with renal 
function and urine dilution in diabetic individuals.
oBjectives: Our goal was to examine associations between the prevalence of diabetes and concen-
trations of As species in exfoliated urothelial cells (EUC) as an alternative to the measures of 
As in urine.
Methods: We measured concentrations of trivalent and pentavalent iAs methyl-As (MAs) and 
dimethyl-As (DMAs) species in EUC from 374 residents of Chihuahua, Mexico, who were exposed 
to iAs in drinking water. We used fasting plasma glucose, glucose tolerance tests, and self-reported 
diabetes diagnoses or medication to identify diabetic participants. Associations between As species 
in EUC and diabetes were estimated using logistic and linear regression, adjusting for age, sex, and 
body mass index.
results: Interquartile-range increases in trivalent, but not pentavalent, As species in EUC were 
positively and significantly associated with diabetes, with ORs of 1.57 (95% CI: 1.19, 2.07) for 
iAsIII, 1.63 (1.24, 2.15) for MAsIII, and 1.31 (0.96, 1.84) for DMAsIII. DMAs/MAs and DMAs/iAs 
ratios were negatively associated with diabetes (OR = 0.62; 95% CI: 0.47, 0.83 and OR = 0.72; 
95% CI: 0.55, 0.96, respectively).
conclusions: Our data suggest that uncertainties associated with measures of As species in urine 
may be avoided by using As species in EUC as markers of iAs exposure and metabolism. Our 
results provide additional support to previous findings suggesting that trivalent As species may be 
responsible for associations between diabetes and chronic iAs exposure.
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have shown that both MAsIII and DMAsIII 
are stable in these cells when stored at –80°C 
(Currier et al. 2011a, 2011b). To increase 
the feasibility of the analysis of MAsIII and 
DMAsIII in the small numbers of EUC that 
are typically available from a spot urine 
sample, we have recently replaced AAS in 
the HG-CT-AAS system with inductively 
coupled plasma–mass spectrometry (ICP-
MS). The newly developed HG-CT-ICP-MS 
was reported to be suitable for the oxidation 
state-specific analysis of As in EUC, providing 
superior detection limits and high reproduc-
ibility (Matoušek et al. 2013).
The goal of the present study was to deter-
mine concentrations of AsIII and AsV species 
in EUC from individuals exposed to iAs in 
drinking water and to examine the association 
between As species in EUC and the  prevalence 
of diabetes.
Materials and Methods
The Chihuahua cohort. All procedures 
involving human subjects were approved by 
institutional review boards at the University 
of North Carolina at Chapel Hill (UNC) and 
Cinvestav-IPN (Centro de Investigación y de 
Estudios Avanzados del Instituto Politécnico 
Nacional, Mexico City, Mexico). Individuals 
participating in the present study were 
among 1,163 men and women recruited for 
the Chihuahua cohort (Mexico); all study 
participants provided informed consent. This 
cohort was established between 2008 and 
2013 to study chronic diseases associated with 
iAs exposure in drinking water. Only adults 
(≥ 18 years of age) with ≥ 5 years of unin-
terrupted residency in the study area were 
recruited. Pregnant women and participants 
who reported kidney or urinary tract infec-
tion were excluded because these conditions 
could affect the urinary pattern of iAs metab-
olites. Individuals with a potential for occu-
pational exposure to As were also excluded. 
Data on residency, occupation, drinking-
water sources and consumption, smoking, 
use of alcohol, drugs, or medication, and 
medical history were gathered at the time of 
enrollment using a questionnaire. Specific 
questions were asked about previous diag-
nosis of diabetes and the use of anti diabetic 
drugs. Samples of household tap water 
were collected for As analysis. The partici-
pants were then transported to Universidad 
Autónoma de Chihuahua to undergo a 
medical examination. Body weight and height 
were recorded and used to calculate BMI. 
A single spot urine sample was collected in 
sterile plastic cups and placed immediately on 
ice. Aliquots of urine samples were frozen and 
stored at –80°C for speciation analysis of As; 
the rest was used for EUC isolation. A single 
sample of fasting venous blood was drawn, 
followed by a standard oral glucose tolerance 
test (OGTT) in which a sample of venous 
blood was drawn 2 hr after an oral load of 
75 g glucose. All blood samples were placed 
on ice immediately after collection. Plasma 
was isolated from the fasting and 2-hr blood 
by centrifugation at 4°C and frozen at –80°C.
Isolation of EUC. EUC were isolated from 
individuals recruited between March 2011 
and August 2012. A total of 466 individuals 
underwent medical examination during this 
period; 428 provided urine for EUC isolation. 
EUCs were isolated from freshly collected 
urine (100 mL/participant) by centrifuga-
tion at 4°C. The cell pellet was washed with 
ice-cold phosphate-buffered saline (PBS) 
and again centrifuged. Cells were then resus-
pended in PBS, counted, and checked for the 
presence of bacteria, yeast, and red or white 
blood cells using a microscope. Only EUC 
free of microbial contamination and with 
< 5% of the total cell count represented by 
red or white blood cells (from a total of 374 
participants) were used in the present study. 
All cells other than bacteria, yeast, and red 
or white blood cells were assumed, but not 
confirmed, to be EUC. EUC were stored 
at –80°C and shipped along with the urine 
samples on dry ice to UNC once per month 
for As speciation analysis.
Diagnosis of diabetes. Glucose levels 
in fasting and 2-hr plasma samples were 
measured using a Prestige 24i Chemistry 
Analyzer (Tokyo Boeki). The analyzer 
was calibrated before analysis, and refer-
ence human sera with normal and elevated 
glucose levels (Serodos and Serodos PLUS; 
Human Diagnostics Worldwide) were used 
for quality control. Study participants with 
fasting plasma glucose (FPG) ≥ 126 mg/dL or 
2-hr plasma glucose (2HPG) ≥ 200 mg/dL, 
or with a self-reported doctor’s diagnosis or 
self-reported use of anti diabetic medication 
were classified as diabetic.
Analyses of As in household water 
and urine. Concentrations of As in acid-
digested water samples were determined at 
Cinvestav-IPN using HG-CT-AAS (Del Razo 
et al. 2011). Urine samples were analyzed 
at UNC after storage at –80°C for up to 
approximately 1 month, which is known to 
result in oxidation of MAsIII and DMAsIII 
(Del Razo et al. 2011). Thus, only analysis 
of total iAs (iAsIII + V), MAs (MAsIII + V), 
and DMAs (DMAsIII + V) was performed 
using HG-CT-AAS (Hernández-Zavala 
et al. 2008a). A certified standard reference 
material (SRM), Arsenic Species in Frozen 
Human Urine (SRM 2669; National 
Institute of Standards and Technology) was 
used with every shipment to assure accuracy. 
The concentrations of As species measured 
by HG-CT-AAS in SRM 2669 ranged 
from 86.7% to 106.4% of the certified 
values: 90.3–106.4% for iAs, 86.7–96.4% 
for MAs, and 88.2–99.0% for DMAs. The 
limits of detection (LODs) using 200 μL 
urine per sample were 0.05 ng As/mL for 
MAs or DMAs and 0.1 ng As/mL for iAs. 
The creatinine concentration in urine was 
determined by a colorimetric assay (Cayman 
Chemical Company); specific gravity was 
measured using a digital Atago PAL refrac-
tometer (Atago USA). It should be noted 
that the HG-CT-AAS cannot detect organic 
As species commonly found in seafood (e.g., 
arsenobetaine), and thus accounts for As 
species associated mainly with iAs exposure.
Analyses of As species in EUCs. AsIII and 
AsV species in EUCs were analyzed at UNC 
using HG-CT-ICP-MS (Matoušek et al. 
2013). Briefly, cell pellets were lysed in 
ice-cold deionized water. The trivalent species 
(AsIII, MAsIII, and DMAsIII) were measured 
in an aliquot of cell lysate directly, without 
pretreatment. Another aliquot was treated 
with 2% cysteine and analyzed for total iAs 
(iAsIII + V), MAs (MAsIII + V), and DMAs 
(DMAsIII + V). The concentrations of iAsV, 
MAsV, and DMAsV were determined as a 
difference between AsIII + V values obtained 
for cysteine-treated aliquots and AsIII values 
from untreated sample aliquots. For AsIII 
species concentrations below LOD, the values 
of LOD divided by the square root of 2 were 
used when calculating the corresponding AsV 
values. Calibration curves were generated 
using cysteine-treated pentavalent As standards 
(at least 98% pure) as previously described 
(Hernández-Zavala et al. 2008a). The instru-
mental LODs for As species analyzed by 
HG-CT-ICP-MS ranged from 0.04 to 2.0 pg 
As. The analyses of As species in EUC were 
performed by a researcher who was unaware 
of the diabetes status of the individual study 
participant or of the As concentrations in the 
corresponding urine and water samples.
Statistical analysis. Continuous variables 
were described using means and SDs or 
medians and inter quartile ranges (IQRs; for 
non normally distributed variables). Categorical 
variables were described using frequencies. 
For As species concentrations below LOD, 
the values of LOD divided by the square 
root of 2 were used for statistical analysis, 
including regression and descriptive analyses 
and to determine IQRs. The statistical signifi-
cance of differences in characteristics of study 
participants with versus without diabetes was 
assessed using Student’s t-tests or one-way 
analyses of variance (ANOVA). Associations 
between As species in EUC and urine were 
estimated using linear regression models with 
log-transformed (log10) variables as well as 
with Spearman correlations. Associations of 
diabetes with concentrations of As species in 
EUC and urine were estimated using logistic 
regression to estimate odds ratios (ORs) and 
95% confidence intervals (CIs). To control 
Currier et al.
1090 volume 122 | number 10 | October 2014 • Environmental Health Perspectives
for potential confounding, sex (as a categorical 
variable) and age and BMI (as continuous 
variables) were included a priori as covari-
ates. We also used linear regression models 
adjusted for age, sex, and BMI to estimate 
associations of log10-transformed FPG and 
2HPG concentrations with concentrations of 
iAs metabolites and the sum of speciated As 
in urine. Age, sex, and BMI were included 
as covariates in these models. The linearity 
of the associations between As species and 
FPG/2HPG was assessed graphically and 
by linear regression using log10-transformed 
values. Slopes were significantly non zero for all 
As species except pentavalent species in EUC. 
Unless otherwise specified, ORs, regression 
coefficients, and CIs are reported for a 1-IQR 
increment of exposure to facilitate comparison 
because of the different concentration ranges 
of As in EUCs and urine. Analyses of urinary 
metabolites of iAs were conducted both with 
and without urinary creatinine concentra-
tion or specific gravity adjustment. All statis-
tical analyses were performed in Epi Info 7, 
version 1.0.6 (Centers for Disease Control 
and Prevention) and graphical representa-
tions were generated using GraphPad Instat 
software package (GraphPad Software Inc.). 
Statistical significance was considered at the 
level of p < 0.05.
Results
Basic characteristics of the study population. 
The EUC samples free of microbial contami-
nation and containing < 5% of red or white 
blood cells were obtained from a total of 374 
participants (252 women and 122 men). More 
than 17% of these participants (17.5% of 
women and 18% of men) were classified as 
diabetic (Table 1) based on the FPG or 2HPG 
value or on their self-reported diabetes diag-
nosis or medication. Eleven participants who 
reported a previous diabetes diagnosis and/or 
taking anti diabetic medication (25.5% of those 
classified as diabetic) had FPG and 2HPG 
values in the normal or prediabetic range (i.e., 
FPG < 126 and 2HPG < 200 mg glucose/dL). 
Approximately 29% of the partici pants were 
overweight and 41% were obese. The average 
age and BMI were significantly higher 
among diabetic compared with non diabetic 
individuals. No statistically significant differ-
ences between diabetic and non diabetic indi-
viduals were found in the average EUC count, 
As concentration in drinking water, or sum of 
As species in urine (expressed either as nano-
grams of As per milliliter or nanograms of As 
per milligram creatinine). The average specific 
gravity of urine from diabetic individuals 
was significantly higher than in non diabetic 
individuals, but the difference between the 
two groups in the sum of As species in urine 
adjusted for specific gravity was not statistically 
significant. The average sum of As species was 
higher in EUC from non diabetic compared 
with diabetic participants; again, this differ-
ence was not statistically significant. Notably, 
basic characteristics of participants included 
in the present study and those of the entire 
Chihuahua cohort were very similar; however, 
the average age of the cohort was somewhat 
lower (see Supplemental Material, Table S1).
Arsenic species in EUC and urine. The 
speciation analysis of As was performed in all 
374 samples of EUC and in the corresponding 
urine samples (Table 2). Concentrations of 
all AsIII and AsV species were above LOD in 
94% of EUC samples. In urine, concentra-
tions of iAs and MAs were below LOD in 
15 (4%) and 2 (0.5%) samples, respectively. 
Table 1. Basic characteristics of the study participants [mean ± SD or n (%)].
Characteristic
Participants
All Diabetica Non diabetic
All participants 374 (100) 66 (17.6) 308 (82.4)
Females 252 (67.4) 44 (17.5) 208 (82.5)
Males 122 (32.6) 22 (18.0) 100 (82.0)
Age (years) 49.2 ± 15.6 56 ± 12.0* 48 ± 16.0*
As in drinking water (ppb) 55.2 ± 52.8 60.0 ± 50.9 54.1 ± 53.2
BMI 29.2 ± 6.1 30.8 ± 5.4* 28.9 ± 6.2*
26 ≤ BMI < 30 108 (29) 19 (29) 79 (26)
BMI ≥ 30 155 (41) 31 (47) 124 (40)
FPG (mg/dL) 95.9 ± 39.5 155.7 ± 62.8* 83.2 ± 12.1*
2HPG (mg/dL) 118.6 ± 60.4 204.9 ± 86.0* 100.4 ± 31.1*
FPG ≥ 126 mg/dL 38 (10.2) 38 (57.6) 0 (0)
2HPG ≥ 200 mg/dL 33 (8.8) 33 (50.0) 0 (0)
Self-reported diabetes diagnosis 43 (11.5) 43 (65.2) 0 (0)
Self-reported diabetes medication 30 (8.0) 30 (45.5) 0 (0)
EUC count in 100 mL urineb 374,008 ± 726,387 352,165 ± 468,388 378,689 ± 771,036
Sum of As speciesc in EUC (pg As/10,000 cells) 127.7 ± 359.6 90.3 ± 202.1 135.7 ± 384.8
Sum of As species in urine (ng As/mL) 73.9 ± 73.2 82.0 ± 74.9 72.1 ± 72.9
Creatinine concentration in urine (mg/dL) 129.2 ± 90.2 127.1 ± 85.7 129.6 ± 91.3
Sum of As species in urine normalized for 
creatinine (ng As/mg creatinine)
65.7 ± 66.5 73.1 ± 77.9 64.2 ± 63.8
Specific gravity of urine 1.014 ± 0.007 1.017 ± 0.008* 1.014 ± 0.007*
Sum of As species in urine normalized for specific 
gravity (ng As/specific gravity unit)
109.7 ± 101.8 92.6 ± 62 113.4 ± 108.2
aDiabetic individuals were classified by either FPG ≥ 126 mg/dL, 2HPG ≥ 200 mg/dL, self-report of doctor diagnosis, 
or use of medication for treatment of diabetes. bNeither red nor white blood cells were included in the cell counts. 
cSum of As species = iAsV + iAsIII + MAsV + MAsIII + DMAsV + DMAsIII. *p < 0.05, for continuous variables, comparing 
participants with and without diabetes by Student’s t-test.





percentile Maximum IQR Mean ± SD
EUC (pg As/10,000 cells)
iAsIII < LODa 2.08 8.18 17.69 1,807 15.61 24.06 ± 103.0
MAsIII < LOD 0.45 1.78 4.04 151.7 3.59 4.17 ± 11.22
DMAsIII < LOD 0.16 0.41 1.54 141.3 1.38 2.73 ± 9.58
iAsV < LOD 1.27 4.53 22.66 728.7 21.39 34.79 ± 86.26
MAsV < LOD 0.19 0.85 5.08 776.2 4.89 13.11 ± 53.48
DMAsV < LOD 0.66 1.90 13.82 2,303 13.16 49.18 ± 200.7
iAsIII + V 0.36 6.35 17.13 41.11 2,148 34.76 58.52 ± 155.2
MAsIII + V 0.04 1.12 3.14 9.84 803.3 8.72 17.25 ± 57.87
DMAsIII + V 0.04 0.88 2.41 15.83 2,366 14.95 51.91 ± 208.9
Sum of As speciesb 0.78 10.05 25.50 76.3 3,773 66.25 127.7 ± 359.6
MAs/iAs 0.01 0.15 0.2 0.28 3.63 0.13 0.26 ± 0.28
DMAs/MAs 0.04 0.55 1.10 2.90 51.47 2.35 2.15 ± 3.64
DMAs/iAs 0.004 0.10 0.20 0.52 35.0 0.42 0.77 ± 2.5
(MAs + DMAs)/iAs 0.02 0.28 0.40 0.79 35.63 0.51 1.03 ± 2.68
Urine (ng As/mL)
iAsIII + V < LOD 0.98 4.62 10.21 119.2 9.23 7.3 ± 10.3
MAsIII + V < LOD 2.23 7.34 15.97 131.1 13.74 11.1 ± 12.9
DMAsIII + V 0.36 13.05 40.46 82.72 307.2 69.67 55.42 ± 53.8
Sum of As species 0.52 17.00 53.50 108.4 492.5 91.40 73.87 ± 73.24
MAs/iAs 0.10 1.28 1.64 2.11 199.4 0.83 4.51 ± 18.1
DMAs/MAs 1.73 4.09 5.19 7.06 86.2 2.97 6.25 ± 5.27
DMAs/iAs 0.41 6.57 9.25 12.43 2,117 5.86 29.1 ± 142.3
(MAs + DMAs)/iAs 0.51 8.07 10.94 14.47 2,317 6.40 33.58 ± 159.6
aThe minimum values were < LOD for iAsIII (n = 3), MAsIII (n = 13), DMAsIII (n = 19), iAsV (n = 6), MAsV (n = 21), or DMAsV 
(n = 3) in EUC, and for iAsIII + V (n = 15) or MAsIII + V (n = 2) in urine. bSum of As species = iAsV + iAsIII + MAsV + MAsIII + 
DMAsV + DMAsIII.
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DMAs was detected and quantified in all 
urine samples. There were marked differences 
in As speciation profiles in EUC and in urine 
(Figure 1). The ratios of DMAs/MAs and 
MAs/iAs were lower in EUC compared with 
urine. In urine, total DMAs (i.e., DMAsIII + V) 
was the predominant species, accounting on 
average for 76% of all As species, with only 
9% and 15% represented by iAs and MAs, 
respectively. In contrast, iAsIII and iAsV were 
the major As species in EUC, representing 
on average 37% and 29% of speciated As. 
DMAs accounted for approxi mately 22% 
(2.4% for DMAsIII and 19.2% for DMAsV) 
and MAs for approximately 14% (MAsIII for 
7.9% and MAsV for 5.6%) of speciated As in 
EUC. In spite of the differences in As specia-
tion profiles, statistically significant positive 
associations were found between the concen-
trations of individual As species in urine 
(not adjusted for creatinine) and EUC (see 
Supplemental Material, Figure S1). Notably, 
adjusting for creatinine had little or no effect 
on these associations (see Supplemental 
Material, Table S2).
EUC counts and As speciation in EUC 
and urine according to sex. We found statisti-
cally significant differences in the numbers of 
EUC obtained from males and females. Cell 
counts in urine from males ranged from 450 
to 2,128,000 cells/100 mL, compared with 
1,800 to 9,717,000 cells/100 mL in samples 
from females. The mean EUC count (± SE) 
was 10 times higher in urine from women 
compared with men (529,258 ± 52,218/100 
mL vs. 53,328 ± 18,782/100 mL). On 
average, EUC from females contained signifi-
cantly less total speciated As ± SD than EUC 
from males: 40 ± 163 pg/10,000 cells versus 
309 ± 542 pg/10,000 cells (see Supplemental 
Material, Figure S2B). For both males and 
females, statistically significant negative 
associations were found between the cell 
count and the concentration of total speci-
ated As in EUC (see Supplemental Material, 
Figure S2). This association was stronger 
for males than females: β = –0.70 (95% CI: 
–0.82, –0.58; r2 = 0.54) versus β = –0.35 
(95% CI: –0.46, –0.23; r2 = 0.12). Sex-related 
differences were also found in the composi-
tion of As species in both EUC and urine 
(Figure 2). iAsIII and MAsIII represented on 
average 43% and 10% of total speciated As 
in EUC from females, but only 18% and 
4% in EUC from males (Figure 2A). On the 
other hand, the pentavalent As species—iAsV, 
MAsV, and DMAsV—accounted for greater 
proportions of As in EUC from males. Taken 
together, iAs species (iAsIII and iAsV) repre-
sented a smaller portion and DMAs species 
(DMAsIII and DMAsV) a greater portion 
of total speciated As in EUC from males 
compared with EUC from females. On 
average, males excreted significantly more As 
in urine as MAsIII + V (17%) than did females 
(14%), but the percentage of DMAsIII + V 
was smaller (73% vs. 78%) (Figure 2B). 
The DMAs/MAs ratio was smaller in male 
compared with female urines: 4.7 ± 1.84 
versus 7.0 ± 6.16 (p < 0.0001).
Associations of diabetes with As species 
in EUC and urine: logistic regression 
analysis. The logistic regression analysis 
was performed using two models. Model 1 
included all diabetic individuals as classi-
fied by FPG, 2HPG, or self-reported diag-
nosis or medication (n = 66). For model 2, 
only individuals with FPG ≥ 126 mg/dL 
or 2HPG ≥ 200 mg/dL were considered 
diabetic (n = 55); 11 individuals who reported 
diabetes diagnosis or medication but had both 
FPG < 126 mg/dL and 2HPG < 200 mg/dL 
were excluded. Both models were adjusted 
for age, sex, and BMI. Using either model, 
we found diabetes to be significantly associ-
ated with iAsIII and MAsIII concentrations in 
EUC—more strongly in model 2, with ORs 
for each IQR of 1.75 (95% CI: 1.29, 2.39) 
and 2.02 (95% CI: 1.48, 2.77), respectively 
(Figure 3; see also Supplemental Material, 
Table S3 for numeric data). In both models 
diabetes was negatively associated with the 
ratios of DMAs/MAs and DMAs/iAs in 
EUCs. Here again, the associations were 
stronger in model 2: OR = 0.53 (95% CI: 
0.38, 0.73) and OR = 0.65 (95% CI: 
0.48, 0.89), respectively. Diabetes was also 
Figure 1. The composition of As species in EUC and 
urine. Data shown are mean + SD (n = 374). 






















Figure 2. Differences in the composition of As species in EUC (A) and urine (B) collected from male and 
female study participants. Data shown are mean + SD (n = 252 for women; n = 122 for men). 





















































Figure 3. Association of diabetes with As species in EUC. In model 1, diabetes was classified by either FPG 
≥ 126 mg/dL, 2HPG ≥ 200 mg/dL, or self-report of doctor diagnosis or use of medication for treatment of 
diabetes; in model 2, diabetes was classified only by FPG ≥ 126 mg/dL or 2HPG ≥ 200 mg/dL. ORs (95% CIs) 
are standardized to an increment of 1 IQR and adjusted for age, sex, and BMI. IQRs for each As species 
and species ratio are shown in Table 2. See Supplemental Material, Table S3, for numeric data. 
*p < 0.05.
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positively associated with DMAsIII and with 
sum of As species in EUC, but these asso-
ciations were statistically significant only for 
model 2 (OR = 1.49, 95% CI: 1.04, 2.13 
and OR = 1.41, 95% CI: 1.01, 1.97, respec-
tively). Diabetes was also positively associ-
ated with total iAsIII + V and MAsIII + V. A 
marginally significant association was found 
with iAsV, but not with other AsV species. 
Notably, adjusting for cell count as a covariate 
in sensitivity analyses had no significant 
impact on the associations between As species 
in EUC and diabetes (data not shown). 
For example, ORs for model 2 were 1.81 
(95% CI: 1.33, 2.48) for iAsIII, 1.93 (95% CI: 
1.42, 2.62) for MAsIII, and 1.42 (95% CI: 
1.02, 1.97) for DMAsIII, thus practically 
matching the values obtained without the 
adjustment (see above).
In urine, total iAs, MAs, and DMAs and 
DMAs/MAs ratio were all positively associated 
with diabetes; however, these associations were 
statistically significant only for the DMAs/
MAs ratio in model 1 (OR = 1.37, 95% CI: 
1.03, 1.84) and total DMAs in model 2 
(OR = 1.34, 95% CI: 1.02, 1.76) (Figure 4; 
see also Supplemental Material, Table S3 for 
numeric data). When adjusted for creatinine, 
total iAs, MAs, DMAs, and sum of As species 
in model 2 were all significantly associated 
with diabetes. In contrast, after adjusting for 
specific gravity all OR values were close to 
zero. Unlike creatinine, specific gravity itself 
was positively associated with diabetes: model 
1, OR = 1.32 (95% CI: 1.01, 1.71); model 2, 
OR = 1.42 (95% CI: 1.07, 1.89).
Associations of diabetes with As species in 
EUC and urine: linear regression analysis. 
Linear regression analysis using logarithmi-
cally (log10) transformed FPG and 2HPG 
values was performed to further characterize 
associations between diabetes and As species 
in EUC and urine (Table 3). Both FPG and 
2HPG were positively associated with the 
trivalent As species (iAsIII, MAsIII, DMAsIII) 
and with the sum of AsIII + V species in EUC 
(p < 0.01), but not significantly associated 
with the pentavalent As species in EUC. 
The ratios of DMAs/MAs and DMAs/iAs in 
EUCs were negatively associated with FPG 
and 2HPG (p ≤ 0.04). Statistically signifi-
cant (p = 0.04) and marginally significant 
(p = 0.08) positive associations were found 
between the MAs/iAs ratio and FPG and 
2HPG, respectively. FPG and 2HPG also 
were significantly associated with each of the 
AsIII + V species in urine, regardless of adjust-
ment for creatinine or specific gravity. Here 
again, specific gravity, but not creatinine, 
was positively associated with both FPG and 
2HPG concentrations (p < 0.01). Both FPG 
and 2HPG were also positively associated 
with the urinary DMAs/MAs ratio.
Discussion
The evidence linking chronic iAs exposure 
to diabetes was reviewed by a 2011 National 
Toxicology Program (NTP) workshop. This 
review concluded that existing data provide 
limited to sufficient support for an asso-
ciation of diabetes with high iAs exposures 
in drinking water (Maull et al. 2012). The 
workshop also discussed methods accounting 
for urine dilution when urinary As is used as 
an indicator of iAs exposure. Because of uncer-
tainties associated with effects of iAs exposure 
or disease on urinary creatinine levels, the 
workshop review recommended that both 
raw and adjusted values should be reported 
(Maull et al. 2012). We followed this recom-
mendation in the present study. We found all 
AsIII + V species in urine to be positively associ-
ated with diabetes classified by FPG or 2HPG. 
When adjusting for creatinine, these associa-
tions were statistically significant in model 2; 
without the adjustment, significant associa-
tion was found only with urinary DMAsIII + V 
(Figure 4; see also Supplemental Material, 
Table S3). Because of the uncertainty asso-
ciated with urinary creatinine, adjusting for 
specific gravity has been recommended as 
an alternative method (Nermell et al. 2008). 
However, adjusting for specific gravity may 
bias associations with diabetes because urine 
of diabetic individuals, compared with healthy 
subjects, contains higher levels of albumin and 
glucose, resulting in higher specific gravity 
(Chadha et al. 2001; Voinescu et al. 2002). 
Indeed, we found a statistically significant 
positive association between diabetes and 
specific gravity and no associations between 
diabetes and urinary As species after adjusting 
for specific gravity.
The main goal of the present study was 
to examine associations between prevalent 
diabetes and As species in EUC as an alterna-
tive marker of iAs exposure and metabolism. 
Because cells provide a reducing environ-
ment, the toxic trivalent arsenicals are rela-
tively stable even in samples stored for weeks 
(Currier et al. 2011a, 2011b). Our results 
show that As species profiles in EUC do not 
reflect those in urine. Specifically, iAs species 
are the major species in EUC but repre-
sent only a small percentage of As found in 
urine, whereas DMAs (i.e., DMAsIII + V) is 
the major urinary metabolite. High iAs levels 
in EUC could be explained by formation of 
iAs-containing intra cytoplasmic and intra-
mitochondrial inclusions. These inclusions 
have recently been found in EUC from 
leukemia patients treated with arsenic trioxide 
(Wedel et al. 2013) and in bladder epithe-
lium of mice exposed to iAs in drinking water 
(Dodmane et al. 2014). We also found that 
the concentrations and proportions of As 
species in EUC significantly differ between 
men and women. EUC from male donors 
contained approximately 10-fold more total 
speciated As than EUC from female donors; 
however, iAsIII and MAsIII accounted for 
smaller fractions of As in male compared with 
female EUC. These differences can probably 
be explained by different cell counts and 
cell types present in urine from males and 
females. The vesical trigone area of an adult 
Figure 4. Association of diabetes with As species in urine, urine creatinine, and specific gravity. Arsenic 
species are either unadjusted (A) or adjusted for creatinine (B) or specific gravity (C). In model 1, diabetes 
was classified by either FPG ≥ 126 mg/dL, 2HPG ≥ 200 mg/dL, or self-report of doctor diagnosis or use of 
medication for treatment of diabetes; in model 2, diabetes was classified only by FPG ≥ 126 mg/dL or 2HPG 
≥ 200 mg/dL. ORs (95% CIs) are standardized to an increment of 1 IQR and adjusted for age, sex, and BMI. 
IQRs for each As species and species ratio are indicated in Table 2. See Supplemental Material, Table S3, 
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female bladder is particularly susceptible to 
squamous metaplasia (Fortin et al. 2010; 
Tyler 1962), a non cancerous change in the 
epithelial lining that is ultimately responsible 
for greater numbers of cells in urine from 
females. Urine from females may also contain 
vaginal epithelial cells. However, the routine 
microscopy used in our study to examine 
EUC suspensions cannot reliably distin-
guish between epithelial cells of urothelial or 
squamous origin. Because of the relatively 
small numbers of cells collected from spot 
urines, we could not apply more sophisticated 
techniques (e.g., immunocytochemistry) to 
characterize the types and origin of EUC. 
Thus, for the purpose of this study we defined 
all cells isolated from the bacteria- and yeast-
free urine containing < 5% of red or white 
blood cells as EUC.
We have previously reported that trivalent 
As species, particularly MAsIII and DMAsIII, 
inhibit insulin-dependent glucose uptake by 
adipocytes (Paul et al. 2007) and glucose stim-
ulated insulin secretion by isolated pancre-
atic islets (Douillet et al. 2013). Our recent 
study in the Zimapan and Lagunera regions 
of Mexico (Del Razo et al. 2011) indicated an 
association between the prevalence of diabetes 
and DMAsIII concentration in urine. In the 
present study, we found positive associations 
of diabetes with iAsIII, MAsIII, and DMAsIII 
concentrations in EUC, thus providing addi-
tional evidence that trivalent metabolites of 
iAs play important roles in the diabetogenic 
effects of iAs exposure. Notably, DMAs/MAs 
and DMAs/iAs ratios in EUC were inversely 
associated with diabetes. Although never 
before measured in EUC, the ratios of As 
species in urine have often been used in popu-
lation studies to evaluate the body capacity 
to methylate iAs. Low DMAs/MAs and high 
MAs/iAs ratios in urine, as possible indicators 
of low methylation capacity, have been linked 
to increased risks of cancer and cardiovascular 
disease in populations chronically exposed to 
iAs exposure (Tseng 2007). In contrast, our 
study in Zimapan and Lagunera (Del Razo 
et al. 2011) and the present study show that in 
the case of diabetes, a high DMAs/MAs ratio 
in urine may be a risk factor.
Conclusions
Our findings provide additional evidence 
for the association between diabetes and 
chronic exposure to iAs and for the role of 
the tri valent metabolites of iAs in the diabeto-
genic effects of this exposure. We also show 
that the speciation analysis of As in EUC—
which facilitates assessment of tri valent 
species and avoids the need for dilution 
adjustments—can be used as an alternative 
to analysis of urinary As species. It should be 
noted, however, that in this study, the results 
obtained using the measures of AsIII species 
in EUC were consistent with the results 
using measures of AsIII + V species in urine 
after adjusting for creatinine. The associa-
tions between diabetes and As species in both 
EUC and urine were stronger when diabetes 
was classified only by FPG ≥ 126 or 2HPG 
≥ 200 mg/dL, disregarding self-reported 
diagnosis or medication. This is consistent 
with a recent report from an American Indian 
cohort (Gribble et al. 2012) where an asso-
ciation between iAs exposure and diabetes 
was observed only among participants with 
poor diabetes control as indicated by elevated 
levels of glycated hemoglobin. Thus, using 
clinical indicators as compared with existing 
diabetes diagnosis may be required to better 
characterize the association of iAs exposure 
with prevalent or incident diabetes. The 
cross-sectional design, which cannot provide 
information on causality of the observed 
associations, and a modest sample size are 
the main limitations of the present study. 
Prospective studies in larger populations 
exposed to iAs, including the Chihuahua 
cohort, are needed to determine whether 
trivalent As species in EUC can be used to 
identify individuals or subpopulations who 
are at risk of developing diabetes as a result of 
chronic exposure to iAs.
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